# Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

> **NCT00650416** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Carvedilol Tablets 12.5 mg
- **DRUG:** Coreg® Tablets 12.5 mg

## Key facts

- **NCT ID:** NCT00650416
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2004-04
- **Final completion:** 2004-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650416, "Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00650416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*